Bioplex analysis of plasma cytokines in Alzheimer’s disease and mild cognitive impairment

Lee, Kang Soo; Chung, Ji Hyung; Lee, Kyung Hye; Shin, Min Jeong; Oh, Byoung Hoon; Hong, Chang Hyung

doi:10.1016/j.imlet.2008.09.004

Cited by 45 publications

(25 citation statements)

References 26 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Nevertheless, another study did not find any significant difference in plasma levels of MCP-1 between AD patients as compared to age-matched controls (Galimberti et al 2003). Lee et al (2008), by means of a multiplex analysis, demonstrated that macrophage migration inhibitory factor (MIF), that stimulates macrophage secretion of TNF-a, IL-1 and IL-8 and induces leukocyte adhesion to capillary walls, was increased both in Mild Cognitive Impairment (MCI) and AD.…”

Section: Inflammatory Peripheral Biomarkersmentioning

confidence: 99%

Peripheral inflammatory biomarkers of Alzheimer’s disease: the role of platelets

et al. 2010

View full text Add to dashboard Cite

Alzheimer's disease is an age-dependent neurodegenerative disorder characterized by loss of neurons, synaptic degeneration, senile plaques and neurofibrillary tangles. Besides these hallmarks, increased accumulation of activated microglia, astrocytes and leukocytes adhering to postcapillary venules are observed in the affected brain areas, suggesting the presence of an ongoing inflammatory process. As neuroinflammation triggers the activation of peripheral immune system, many studies have analyzed circulating inflammatory biomarkers, including basal or stimulated levels of cytokines and related molecules in blood of Alzheimer's patients, but with conflicting results. Platelets are an important source of amyloid-ss (Ass) in the circulatory system and play an important pro-inflammatory role. Upon activation, they adhere to leukocytes and endothelial cells by means of adhesive proteins like P-selectin, platelet endothelial cell adhesion molecule-1 (PECAM) and intercellular adhesion molecule-1 and -2 (ICAM-1 and -2) and secrete inflammatory mediators (chemokines, interleukins). In addition, platelets contain important enzymes involved in inflammatory intermediary synthesis like phospholipase A(2) (PLA(2)) and cyclooxygenase-2 (COX-2), and recent reports demonstrated significant changes in platelet levels and activities in Alzheimer's disease. Thus, as platelets represent an important link between Ass deposition and inflammatory reactions especially at endothelial level, they can be considered a valuable cellular model to evaluate potential peripheral inflammatory biomarkers in Alzheimer's disease.

show abstract

Section: Inflammatory Peripheral Biomarkersmentioning

confidence: 99%

Peripheral inflammatory biomarkers of Alzheimer’s disease: the role of platelets

et al. 2010

View full text Add to dashboard Cite

show abstract

“…MIF shares many functional features with chemokines and has therefore been classified as having a chemokine-like function. One study has demonstrated that MIF levels are higher in AD patients than in patients without cognitive impairment [47] .…”

Section: Macrophage Migration Inhibitory Factormentioning

confidence: 99%

“…One study has demonstrated that MIG levels are higher in AD patients than in patients with either no or mild cognitive impairment [47] . In this study, which measured levels of both interferon-inducible protein 10 (IP-10, which is usually activated together with MIG) and MCP-1 (which, like MIG, acts on monocytes/macrophages), it was found that plasma MIG levels correlated with IP-10 levels, but not with MCP-1 levels.…”

Section: Macrophage Migration Inhibitory Factormentioning

confidence: 99%

Peripheral Cytokines and Chemokines in Alzheimer’s Disease

Lee

Chung²,

Choi³

et al. 2009

Dement Geriatr Cogn Disord

Self Cite

122

View full text Add to dashboard Cite

A chronic inflammatory process has been implicated in the neuropathology of Alzheimer’s disease (AD). The present review focuses on the current knowledge of circulating serum and plasma biomarkers of AD that are linked to inflammatory reactions. There is abundant evidence that inflammatory mechanisms within the central nervous system contribute to cognitive impairment via cytokine-mediated interactions between neurons and glial cells. Interleukins 1, 4, 6, 10, 12, 16, and 18, tumour necrosis factor, and several chemokines have been suggested as biomarkers of AD. Nonetheless, data on circulating cytokine levels are somewhat inconsistent with regard to peripheral cytokine dysregulation in AD. In summary, definite statements concerning differences in inflammatory biomarkers between controls and AD patients will require the use of sensitive multiplex assays in large patient groups in conjunction with measures of disease severity.

show abstract

“…It has been demonstrated that C3, a factor contained in amyloid-beta plaques, has an active role in the genesis of the senile plaques [32], but the expression of C3 did not differ significantly between AD cases and age-matched controls in the work presented by Fischer [33]. Although MCP3 has been analyzed in several studies [34,35], it has not shown significant difference in expression levels between AD subjects and controls. Also, the volume of the angular gyrus, whose role was previously discussed, and the CMRgl of the temporal gyrus, a widely accepted biomarker, were part of the the proposed model.…”

Section: Discussionmentioning

confidence: 96%

Improved multimodal biomarkers for Alzheimer's disease and mild cognitive impairment diagnosis: data from ADNI

2013

View full text Add to dashboard Cite

The accurate diagnosis of Alzheimer's disease (AD) and mild cognitive impairment (MCI) confers many clinical research and patient care benefits. Studies have shown that multimodal biomarkers provide better diagnosis accuracy of AD and MCI than unimodal biomarkers, but their construction has been based on traditional statistical approaches. The objective of this work was the creation of accurate AD and MCI diagnostic multimodal biomarkers using advanced bioinformatics tools. The biomarkers were created by exploring multimodal combinations of features using machine learning techniques. Data was obtained from the ADNI database. The baseline information (e.g. MRI analyses, PET analyses and laboratory essays) from AD, MCI and healthy control (HC) subjects with available diagnosis up to June 2012 was mined for case/controls candidates. The data mining yielded 47 HC, 83 MCI and 43 AD subjects for biomarker creation. Each subject was characterized by at least 980 ADNI features. A genetic algorithm feature selection strategy was used to obtain compact and accurate cross-validated nearest centroid biomarkers. The biomarkers achieved training classification accuracies of 0.983, 0.871 and 0.917 for HC vs. AD, HC vs. MCI and MCI vs. AD respectively. The constructed biomarkers were relatively compact: from 5 to 11 features. Those multimodal biomarkers included several widely accepted univariate biomarkers and novel image and biochemical features. Multimodal biomarkers constructed from previously and non-previously AD associated features showed improved diagnostic performance when compared to those based solely on previously AD associated features.

show abstract

Bioplex analysis of plasma cytokines in Alzheimer’s disease and mild cognitive impairment

Cited by 45 publications

References 26 publications

Peripheral inflammatory biomarkers of Alzheimer’s disease: the role of platelets

Peripheral inflammatory biomarkers of Alzheimer’s disease: the role of platelets

Peripheral Cytokines and Chemokines in Alzheimer’s Disease

Improved multimodal biomarkers for Alzheimer's disease and mild cognitive impairment diagnosis: data from ADNI

Contact Info

Product

Resources

About